<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Sinclair, Heather Q.</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Diener, Hans-Christophe</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">How Does Dabigatran Compare with Warfarin for Secondary Stroke Prevention? Subgroup Analysis of the RE-LY Study</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-03-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">14-15</style></pages><abstract><style  face="normal" font="default" size="100%">A subgroup analysis of the Randomized Evaluation of Long-term anticoagulant therapy [RE-LY; NCT00262600] trial revealed that dabigatran 110 mg or 150 mg twice daily is as effective as warfarin for stroke prevention in patients who have had a prior stroke or transient ischemic attack.</style></abstract><number><style face="normal" font="default" size="100%">1</style></number><volume><style face="normal" font="default" size="100%">10</style></volume></record></records></xml>